Almirall's Nine-month 2023 Results: - PharmiWeb.com

Almirall achieves Net Sales growth of 6.4%, driven by strong European dermatology performanceAlmirall's European Dermatology business continued to be the driving force behind Almirall's strong performance in the first nine months of 2023, with a growth rate of 15.9% underpinned by the success of Ilumetri® and other...

Related Keywords

Hong Kong ,United States ,Italy ,Switzerland ,Denmark ,Spain ,United Kingdom ,Germany ,Netherlands ,Berlin ,Macau ,Barcelona ,Comunidad Autonoma De Cataluna ,Taiwan ,China ,Austria ,Spanish ,Chinese ,Eli Lilly ,Omar Ram ,Epimab Biotherapeutics ,Astra Zeneca Covis ,Simcere Pharmaceutical Group For ,Committee For Medicinal Products Human Use ,Simcere Pharmaceutical Group ,European Commission ,European Medicines Agency ,European Union ,Corporate Communications ,Venereology Congress ,Chinese National Medical Products Administration ,Spanish Stock Exchange ,European Association Of Dermatology ,Healthcare Products Regulatory Agency ,European Academy Of Dermatology ,Net Sales ,European Dermatology ,New Drug Application ,Astra Zeneca ,Net Debt ,Gallardo Piqu ,European Association ,Medicinal Products ,Human Use ,European Academy ,Global Assessment ,Eczema Area ,Severity Index ,Annual Fall Clinical Dermatology Conference ,Large Field ,Ichnos Science ,Greater China ,Mainland China ,Fabs In Tandem Immunoglobulin ,Noble Purpose ,Safe Treatment ,Psoriatic Disease ,Real World Prospective Cohort Study ,Patient Reported Outcomes ,Tirbanibulin Effectiveness ,Cutaneous Medicine ,Lebrikizumab Is Maintained ,Two Years ,Clinical Dermatology ,